Business Description
Alto Neuroscience Inc
NAICS : 541713
SIC : 2836
ISIN : US02157Q1094
Description
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 20.56 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.42 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.02 | |||||
9-Day RSI | 34.01 | |||||
14-Day RSI | 37.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 26.02 | |||||
Quick Ratio | 26.02 | |||||
Cash Ratio | 25.72 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -46.6 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -122.49 | |||||
ROA % | -21.13 | |||||
ROIC % | -1365.35 | |||||
ROC (Joel Greenblatt) % | -1968.63 | |||||
ROCE % | -21.74 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.51 | |||||
Price-to-Tangible-Book | 1.51 | |||||
EV-to-EBIT | -4.17 | |||||
EV-to-EBITDA | -4.21 | |||||
EV-to-FCF | -4.33 | |||||
Price-to-Net-Current-Asset-Value | 1.52 | |||||
Price-to-Net-Cash | 1.54 | |||||
Earnings Yield (Greenblatt) % | -23.98 | |||||
FCF Yield % | -7.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:ANRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alto Neuroscience Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.199 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 37.46 | ||
14-Day ATR ($) | 0.749579 | ||
20-Day SMA ($) | 11.7975 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 10.695 - 24 | ||
Shares Outstanding (Mil) | 26.88 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Alto Neuroscience Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Alto Neuroscience Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Alto Neuroscience Inc Frequently Asked Questions
What is Alto Neuroscience Inc(ANRO)'s stock price today?
The current price of ANRO is $10.85. The 52 week high of ANRO is $24.00 and 52 week low is $10.70.
When is next earnings date of Alto Neuroscience Inc(ANRO)?
The next earnings date of Alto Neuroscience Inc(ANRO) is 2024-08-30 Est..
Does Alto Neuroscience Inc(ANRO) pay dividends? If so, how much?
Alto Neuroscience Inc(ANRO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |